Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor–associated tumors

2012155 citationsJournal Article

Authors

Tivantinib was safe and tolerable in patients with MiT tumors, but antitumor activity was modest.

Good health and well-being

Published in: Cancer

Volume 118, Issue 23, pp. 5894-5902

Field-Weighted Citation Impact: 14.40